FDA Fast-Tracks Psychedelic Treatments for Veterans, Depression

The FDA awarded priority review vouchers to three psychedelic drug programs on April 24, bringing hope to veterans and Americans trapped by treatment-resistant depression, PTSD, and alcohol use disorder. The action fulfills a Trump executive order directing the agency to accelerate clinical research into therapies for some of the most stubborn mental health conditions facing the country today.

The move reflects a deliberate administration strategy to advance legitimate medical research through established FDA pathways. Officials frame this not as counterculture liberalization, but as evidence-based medicine putting veterans and patients first.

All three recipients already carry Breakthrough Therapy designations, the FDA's most stringent scientific validation. Compass Pathways develops psilocybin for treatment-resistant depression, Usona Institute targets major depressive disorder with psilocybin, and Transcend Therapeutics is pursuing methylone for PTSD.

The awards mark the first time the agency has fast-tracked any psychedelic candidate. The decision signals a sharp policy reversal from previous administrations.

The Commissioner's National Priority Voucher program, launched in June 2025, shrinks NDA review timelines from 10 to 12 months down to just one or two. Eli Lilly's Foundayo became the first CNPV-assisted approval earlier this year, clearing regulatory hurdles in 50 days after NDA submission.

Usona Institute confirmed that "the voucher accelerates FDA review to approximately one to two months, but it does not alter scientific or regulatory standards."

FDA Commissioner Marty Makary stressed that development must remain "grounded in sound science and rigorous clinical evidence." Speaking to CNN, he noted that approved drugs would be "given in a controlled, supervised setting in a hospital" — "not medications you'll just pick up at a pharmacy."

President Trump signed "Accelerating Medical Treatments for Serious Mental Illness" on April 18, directing the FDA to issue CNPVs to appropriate psychedelic drugs bearing Breakthrough Therapy designation. The order allocates $50 million through ARPA-H for state-level research and mandates VA collaboration.

HHS Secretary Robert F. Kennedy Jr. stated the FDA will "prioritize therapies with Breakthrough Therapy designation, where early evidence shows meaningful improvement over existing options."

The clinical data behind these approvals carries weight. Compass has generated positive results from two large, well-controlled Phase 3 trials, with CEO Kabir Nath confirming the company's robust evidence base. Transcend's methylone achieved statistically significant results in a Phase 2 trial with 65 patients — a placebo-adjusted CAPS-5 improvement of minus 8.00 by Day 10, sustained through Day 64 at minus 9.64, with no hallucinations or discontinuations due to adverse events.

In a parallel development, the FDA authorized the first U.S. clinical study of an ibogaine derivative — noribogaine hydrochloride by DemeRx NB — for alcohol use disorder. Nearly 28 million Americans, or one in 10, have AUD.

Dr. Deborah Mash, DemeRx founder, first studied ibogaine in the 1990s before NIDA pulled federal funding over cardiovascular toxicity concerns. Her noribogaine metabolite reportedly lacks the hallucinogenic effects and cardiac risks of the original compound.

"Every grant proposal that I submitted to the National Institute on Drug Abuse was rejected," Mash told The Associated Press. "I couldn't get that funding and that's why ibogaine didn't advance in the 1990s."

The executive order centers on veteran health. More than 14 million American adults have serious mental illness, and veteran suicide rates exceed twice the non-veteran rate. Over 6,000 veterans have died by suicide annually for more than two decades.

Former Navy SEAL Marcus Luttrell and podcaster Joe Rogan attended the April 18 signing. Luttrell told Trump, "It absolutely changed my life for the better."

The policy represents a reversal from October 2025, when Compass appeared on a draft CNPV list but was reportedly blocked by the White House. Resilient Pharmaceuticals' MDMA-assisted therapy for PTSD did not receive a voucher, despite having received a Complete Response Letter in August 2024. That letter cited failure to collect positive adverse events, lack of durability data, and high rates of prior MDMA use among participants.

The distinction demonstrates the FDA maintains scientific standards in voucher distribution.

"Under President Trump's leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments — including psychedelic therapies like ibogaine — to confront our nation's mental health crisis head-on, especially for our veterans," Kennedy said.

All psychedelics remain Schedule I substances under federal law. Makary explained that the FDA has a system with the DEA allowing "transient de-scheduling" exemptions for hospital or clinic administration under clinical supervision. The agency intends to release final guidance imminently for sponsors developing psychedelic medications, addressing "unique scientific and methodological challenges."

Some experts raised concerns about White House direction of FDA priorities. "There are many people who think that this avenue shows promise in the mental health space," said Dan Troy, former FDA chief counsel. "I think the concern that some of us have is whether or not the White House should be telling the FDA which medicines to prioritize."

The American Psychiatric Association welcomed federal investment but emphasized that "rigorous study, strong patient protections, and physician-led oversight will be essential to ensure safety and effectiveness." At least 21 states are considering psychedelic-related legislation, with Oregon and Colorado having already legalized psilocybin therapy.

The executive order signals that federal-level medical research into these compounds will accelerate. The framework places strict clinical oversight at the center — not recreational liberalization — aligning with conservative priorities of veteran care, scientific innovation, and evidence-based medicine.

For the families who have watched loved ones struggle through years of failed treatments, the voucher system offers something concrete. Faster review means faster answers. And for millions of Americans carrying the weight of conditions that have resisted conventional therapy, those answers could come sooner than anyone expected.